ERBB2 and acute myeloid leukemia: Because HER2 is not the target of TAK165 and ATRA and the transcriptional activation of RARα is generally considered to be the classical mechanism for the differentiating effect of ATRA14, 15, 16, 17, we then hypothesized that TAK165 might potentiate the RARα sensitization of ATRA on AML cells.